Cellares partnered with Papillon Therapeutics to scale manufacturing for PPL-001, a CRISPR-based cell therapy candidate for Friedreich’s ataxia. The collaboration will focus on transferring the therapy onto Cellares’s cell-shuttle manufacturing approach, covering end-to-end process execution as Papillon moves toward broader clinical deployment. PPL-001 is designed to remove a pathogenic GAA repeat expansion in the FXN gene using CRISPR editing in hematopoietic stem and progenitor cells, then deliver corrected cells via bone-marrow engraftment. Papillon positions the approach as one-time delivery aimed at addressing multi-tissue disease biology rather than symptom-only treatment. For gene therapy logistics and scale, the deal matters because orphan cell therapies depend on manufacturing repeatability and supply chain planning as patient numbers grow. The partnership also signals continuing CDMO competition centered on program-specific manufacturing architectures and quality systems.